China Medical University at Taichung

www.cmu.edu.cn
Taichung, Taiwan
SEARCH FILTERS
Time filter
Source Type

Patent
Kaohsiung Chang Gung Memorial Hospital Of The Cgmf and China Medical University at Taichung | Date: 2017-04-11

A method for treating a subject afflicted with dementia is disclosed. The method comprises administering to the subject a composition comprising an effective amount of a benzoic acid, a salt, an ester, or a derivative thereof, and a pharmaceutically acceptable carrier or vehicle, wherein the subject is not administered any other neuropharmaceutical.


Patent
China Medical University at Taichung and National Taiwan University | Date: 2016-06-30

A use of an active ingredient in the manufacture of a medicament or a preparation is provided, wherein the active ingredient is at least one of ergstatrien-3-ol and a pharmaceutically acceptable ester thereof, the medicament is for alleviating, inhibiting and/or treating the hepatic injuries caused by alcohol consumption, or for alleviating and/or inhibiting body fat accumulation caused by alcohol consumption, and the preparation is a food or a food additive for increasing the alcohol metabolism capability of the liver.


A phenanthroindolizidine and phenanthroquinolizidine alkaloid having a hydroxyl group on the phenanthrene ring thereof was synthesized, which exhibits potent activity as an anticancer agent against, such as breast cancer, lung cancer, and prostate cancer.


A method of evaluating if a glioblastoma multiforme (GBM) patient is applicable to be treated with an immunotherapy based on dendritic cell tumor vaccines includes a sample obtaining step to obtain a sample from the GBM patient, a detecting step to detect an expression level of a biomarker, and a comparing step to compare the expression level of the biomarker to a threshold, wherein the GBM patient is applicable to treat with the immunotherapy based on dendritic cell tumor vaccines when the expression level of the biomarker is lower than the threshold. A method of prognosticating a survival rate in the GBM patient after a treatment includes a sample obtaining step, a detecting step, and a comparing step, wherein the GBM patient is determined to have a good prognosis after the treatment when the expression level of the sample from the GBM is lower than the threshold.


A method of evaluating if a glioblastoma multiforme (GBM) patient is applicable to be treated with an immunotherapy based on dendritic cell tumor vaccines includes a sample obtaining step to obtain a sample from the GBM patient, a detecting step to detect an expression level of a biomarker, and a comparing step to compare the expression level of the biomarker to a threshold, wherein the GBM patient is applicable to treat with the immunotherapy based on dendritic cell tumor vaccines when the expression level of the biomarker is lower than the threshold. A method of prognosticating a survival rate in the GBM patient after a treatment includes a sample obtaining step, a detecting step, and a comparing step, wherein the GBM patient is determined to have a good prognosis after the treatment when the expression level of the sample from the GBM is lower than the threshold.


Patent
Taipei Medical University and China Medical University at Taichung | Date: 2015-06-04

The present invention develops a series of methyl caffeate derivatives having biological activity in anti-angiogenesis. The present invention suggests that the compounds of the invention possess inhibiting angiogenesis through regulation of VEGF/VEGFR-2 and its downstream signaling cascades in the vascular endothelial cells (VECs).


A mesenchymal stem cell is provided. The mesenchymal stem cell that expresses an insulin-like growth factor 1 receptor have been cultured in media containing human cord blood serum and isolated, such that an insulin-like growth factor 1 receptor expression is enhanced in the isolated mesenchymal stem cells.


Patent
China Medical University at Taichung | Date: 2016-03-09

A pharmaceutical composition for inhibiting the autophagy of motor neurons comprising an effective amount of an active ingredient selected from the group consisting of a compound of formula (I), a pharmaceutically acceptable salt of the compound, a pharmaceutically acceptable ester of the compound and combinations thereof:_(1) is H or a substituted or unsubstituted C1-C20 alkyl, wherein one or more -CH_(2)- of the C1-C20 alkyl are optionally being replaced by -NH- or -O-.


Patent
China Medical University at Taichung | Date: 2016-03-09

A use of an ergothioneine is disclosed. The use of the ergothioneine is manufacture of a product for inducing an activity of an Nrf2 in a cell, wherein the cell is a normal cell or a damaged cell resulting from an exposure to an ultraviolet radiation (UVR).


This invention discloses methods for regulating multiple organs, multiple genes and multiple targets by using a polypeptide, wherein the polypeptide comprising the amino acid sequence of SEQ ID No.1 and/or homology thereof. The present polypeptide reveals the potency to regulate transcription of multiple genes and expression of multiple targets. Therefore, a composition having the polypeptide can be applied to regulate the expression of multiple targets in multiple organs of patients. Furthermore, the composition having the polypeptide can be applied in therapies of inflammation and inflammatory disorders, suppression of fatty liver disease progression, suppression of the diseases caused by fatty accumulation, prevention and therapy of muscular atrophy, and avoiding the complications of diabetes.

Loading China Medical University at Taichung collaborators
Loading China Medical University at Taichung collaborators